CBG kills pancreatic tumor cells in vitro

The most common form of pancreatic cancer is pancreatic ductal adenocarcinoma (PDAC). It has a poor prognosis primarily due to its chemotherapy resistance - less than 10% survival rate after 5 years.

This study examined the effectiveness of a single dose of CBG on cell models (in vitro) of PDAC. It was published in February 2024 in the International Journal of Molecular Sciences.

A single dose of CBG isolate was applied to several different types of pancreatic cancer cell cultures to determine its effect after 48 or 72 hours. They also applied single doses to healthy human cell lines to determine their toxicity.


Additionally, CBG was combined with some standard chemotherapy treatments: gemcitabine (GEM) and paclitaxel (PTX) to determine if there were any synergistic effects.

Overall they found a positive dose response relationship - higher doses of CBG caused more cancer cell death. And they found adding CBG to two standard chemotherapy drugs was more cytotoxic to cancer cells than the chemotherapy drugs alone.

The methods used to quantify results in this type of study are complex. The details are covered in the full text article (link at end). However, the results in the authors' words are less complex:

CBG Inhibits Cell Growth of PDAC Cell Lines

CBG Induces Autophagy

CBG Induces Apoptosis in PDAC Cell Lines

The Combination of CBG with PTX or GEM Induces Higher Cytotoxicity Compared to Administration of Single Drugs in PDAC Cell Lines


The authors' concluded:

our results showed that CBG, a non-psychomimetic cannabinoid from Cannabis Sativa L., can induce an anticancer effect in two human PDAC cell lines, supporting the ability of cannabinoids to interfere with several pro-tumoral pathways



The full text article is here at MDPI.com.



Zeppa, L.; Aguzzi, C.; Morelli, M.B.; Marinelli, O.; Giangrossi, M.; Luongo, M.; Amantini, C.; Santoni, G.; Nabissi, M. Cannabigerol Induces Autophagic Cell Death by Inhibiting EGFR-RAS Pathways in Human Pancreatic Ductal Adenocarcinoma Cell Lines. Int. J. Mol. Sci. 202425, 2001. https://doi.org/10.3390/ijms25042001